Active ingredient
- denosumab
Legal Category
POM: Prescription only medicine
POM: Prescription only medicine
This reminder card contains important safety information that patients need to be aware of before and during treatment with denosumab (Prolia), which is used to treat osteoporosis and bone loss. A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported rarely (may affect up to 1 in 1,000 people) in patients receiving Prolia for osteoporosis. ONJ can also occur after stopping treatment. It is important to try to prevent ONJ developing as it may be a painful condition that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions patients should take. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441
If you would like to make a comment or send us feedback on this material, click here.
216 Cambridge Science Park, Milton Road, Cambridge, CB4 0FZ
+44 (0)1223 426 314
+44 (0)1223 426 314
+44 (0)1223 420 305
+44 (0)1223 436 441
+44 (0)808 0100 321